ONCOLYTICS BIOTECH INC
ONCY
Analytical Summary
On an absolute basis, ONCOLYTICS BIOTECH INC shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.
7-Year Financial Trajectory
Quarterlyinfo Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.
Bullish Indicators
- Return on Invested CapitalReturn on Invested Capital of 758.2% is excellent on an absolute basis (target > 10%)
Bearish Risks
- FCF / Net IncomeFCF / Net Income of 0.70x is weak on an absolute basis (target > 1x)
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|
| EPS Growth YoY (%) |
-33.3%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
-33.3%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — | — | — |
| Net Income Growth YoY (%) |
-78.9%
Weak
Weak
Year-over-year change in net income |
-96.2%
Weak
Weak
Year-over-year change in net income |
— | — | — | — | — |
| FCF Growth YoY (%) |
-50.6%
Weak
Weak
Year-over-year change in free cash flow |
-16.2%
Weak
Weak
Year-over-year change in free cash flow |
— | — | — | — | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
-1.1%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — |
-1.2%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — | — |
| FCF / Net Income (x) |
0.86x
Caution
↑
Caution
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.79x
Caution
↓
Caution
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
0.78x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.00x
Fair
Fair
Free cash flow relative to reported net income
Optimal:
> 1x
|
— | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|
| Return on Invested Capital (%) |
153.7%
Excellent
↑
Excellent
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
142.9%
Excellent
↑
Excellent
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
-127.2%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-106.5%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — |
| Return on Capital (%) (%) |
-122.3%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-113.7%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — | — | — |
| Return on Common Equity (%) (%) |
153.1%
Excellent
↑
Excellent
Improving
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+921%)
|
180.2%
Excellent
↑
Excellent
Improving
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+1101%)
|
— |
-142.7%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1051%)
|
-126.5%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-943%)
|
— | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|
| Working Capital (USD) | $1.84M | $2.06M | $743.00K | — | — | $7.55M | — |
| Total Equity (USD) | $-6.17M | $-5.13M | $-3.80M | $3.70M | $3.73M | $3.30M | $19.60M |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|
| Depreciation Expense (USD) | $15.00K | $16.00K | — | $18.00K | $19.00K | — | — |
| Net Income, GAAP (USD) | $-9.44M | $-9.24M | — | $-5.28M | $-4.71M | — | — |
| Operating Cash Flow (USD) | $-8.14M | $-7.29M | — | $-4.11M | $-4.73M | — | — |
Secondary lens
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Unavailable
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Benchmarks unavailable
Verdicts use absolute quality thresholds, not peer comparison — only 0 comparable companies are currently available for ranking.
Use Statement Evidence firstCompare ONCY with peers
Stack ONCY against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced yesterday 3 years · 7 quarters